Advertisement

THE PROTECTIVE EFFECTS OF TYPE-1 INTERFERON IN MODELS OF INTESTINAL INFLAMMATION

  • Jongdae Lee
  • Kazumichi Abe
  • Kyoko Katakura
  • Jose Gonzalez-Navajas
  • Eyal Raz
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 633)

1 Introduction

Inflammatory bowel disease (IBD) including both Crohn’s disease and ulcerative colitis is characterized by episodes of intestinal inflammation that can reoccur throughout life. Clinical and experimental evidence suggests that the etiology of IBD is multifactorial and includes susceptibility genes related to innate immunity (e.g., Nod2, IL-23R) as well as environmental factors,4, 5, 6,10,13,14 such as exposure to intestinal microflora and/or their products. It is believed that the interaction of these factors with the immune system leads to dysregulated mucosal immunity and chronic intestinal inflammation. Different models of experimental colitis have been instrumental in defining the fundamental molecular mechanisms and cellular interplay that lead to colonic inflammation in mice as well as humans.

The acute colitis that is induced in mice by a single oral administration of dextran sulfate sodium (DSS) is the result of a T cell independent inflammatory reaction. This...

Keywords

Inflammatory Bowel Disease Dextran Sulfate Sodium Intestinal Inflammation TLR9 Ligand Diphtheria Toxin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This work was supported by NIH grants AI40682, AI68685, DK35108 and a grant from the CCFA. We thank Mrs. L. Beck for her editorial assistance.

References

  1. 1.
    Abe K, Nguyen KP, Fine SD, Mo J-H, Shen C, Shenouda S, Corr M, Jung S, Lee J, Eckmann L, Raz E (2007) Conventional dendritic cells regulate the outcome of colonic inflammation independently of T cells. Proc Natl Acad Sci USA (in press )<bib id="bib1"> <no>1.</no> Abe K, Nguyen KP, Fine SD, Mo J-H, Shen C, Shenouda S, Corr M, Jung S, Lee J, Eckmann L, Raz E (2007) Conventional dendritic cells regulate the outcome of colonic inflammation independently of T cells. Proc Natl Acad Sci USA (in press<auQuery ID="AU2">[AU2]</auQuery>)</bib> Google Scholar
  2. 2.
    Akira S (2001) Toll-like receptors and innate immunity. Adv Immunol 78:1–56CrossRefPubMedGoogle Scholar
  3. 3.
    Akira S, Hemmi H (2003) Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 85:85–95CrossRefPubMedGoogle Scholar
  4. 4.
    Dubinsky MC, Wang D, Picornell Y, Wrobel I, Katzir L, Quiros A, Dutridge D, Wahbeh G, Silber G, Bahar R, Mengesha E, Targan SR, Taylor KD, Rotter JI (2007) IL-23 receptor (IL-23R) gene protects against pediatric Crohn’s disease. Inflamm Bowel Dis 13:511–515CrossRefPubMedGoogle Scholar
  5. 5.
    Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH (2006)A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314:1461–1463CrossRefPubMedGoogle Scholar
  6. 6.
    Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O’Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411:599–603CrossRefPubMedGoogle Scholar
  7. 7.
    Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T, Wu S, Vuthoori S, Ko K, Zavala F, Pamer EG, Littman DR, Lang RA (2002) In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 17:211–220CrossRefPubMedGoogle Scholar
  8. 8.
    Katakura K, Lee J, Rachmilewitz D, Li G, Eckmann L, Raz E (2005) Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest 115:695–702PubMedGoogle Scholar
  9. 9.
    Lee J, Mo JH, Katakura K, Alkalay I, Rucker AN, Liu YT, Lee HK, Shen C, Cojocaru G, Shenouda S, Kagnoff M, Eckmann L, Ben-Neriah Y, Raz E (2006) Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 8:1327–1336CrossRefPubMedGoogle Scholar
  10. 10.
    Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 411:603–606CrossRefPubMedGoogle Scholar
  11. 11.
    Rachmilewitz D, Karmeli F, Takabayashi K, Hayashi T, Leider-Trejo L, Lee J, Leoni LM, Raz E (2002) Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 122:1428–1441CrossRefPubMedGoogle Scholar
  12. 12.
    Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K, Raz E (2004) Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126:520–528CrossRefPubMedGoogle Scholar
  13. 13.
    Watanabe T, Kitani A, Murray PJ, Wakatsuki Y, Fuss IJ, Strober W (2006) Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity 25:473–485CrossRefPubMedGoogle Scholar
  14. 14.
    Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448:427–434CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Jongdae Lee
    • 1
  • Kazumichi Abe
  • Kyoko Katakura
  • Jose Gonzalez-Navajas
  • Eyal Raz
  1. 1.Division of Rheumatology Allergy and ImmunologyUniversity of CaliforniaSan DiegoUSA

Personalised recommendations